Lorenzo Facila Rubio, Vicente Pallarés-Carratalá, Alberto Cordero, José Pérez Silvestre, Clara Bonanad Lozano
{"title":"Herpes Zoster Vaccination as Cardiovascular Prevention in Adults with Heart Disease.","authors":"Lorenzo Facila Rubio, Vicente Pallarés-Carratalá, Alberto Cordero, José Pérez Silvestre, Clara Bonanad Lozano","doi":"10.1007/s10557-026-07966-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To summarize the evidence linking herpes zoster (HZ) with cardiovascular events and assess whether HZ vaccination may reduce cardiovascular risk, with particular attention to the transition from live attenuated vaccine (ZVL) to adjuvanted recombinant vaccine (RZV).</p><p><strong>Methods: </strong>Narrative review structured around SANRA quality domains, based on searches of PubMed/MEDLINE, Embase, Cochrane CENTRAL, ClinicalTrials.gov, and guideline and grey-literature sources through 12 August 2026, with two peer-review-identified sources added thereafter.</p><p><strong>Results: </strong>HZ is associated with a transient increase in stroke and myocardial infarction risk, particularly after ophthalmic HZ. The strongest population-level cardiovascular evidence concerns ZVL, with a South Korean cohort showing reductions in major cardiovascular events, heart failure, and stroke sustained for up to 8 years; ZVL is now withdrawn in the United States and European Union. A natural-experiment study directly comparing the platforms found a further 9% reduction in cardiovascular burden with RZV versus ZVL over 7 years. Real-world cohorts in high-risk populations and a peer-reviewed meta-analysis also support cardiovascular benefit, although most pooled analyses combine RZV and ZVL, and no randomized trial has been designed specifically for cardiovascular outcomes.</p><p><strong>Conclusion: </strong>Evidence increasingly supports a cardiovascular benefit of HZ vaccination, including with RZV currently in use, but remains predominantly observational or quasi-experimental. Dedicated randomized cardiovascular-outcome trials are needed.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-026-07966-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To summarize the evidence linking herpes zoster (HZ) with cardiovascular events and assess whether HZ vaccination may reduce cardiovascular risk, with particular attention to the transition from live attenuated vaccine (ZVL) to adjuvanted recombinant vaccine (RZV).
Methods: Narrative review structured around SANRA quality domains, based on searches of PubMed/MEDLINE, Embase, Cochrane CENTRAL, ClinicalTrials.gov, and guideline and grey-literature sources through 12 August 2026, with two peer-review-identified sources added thereafter.
Results: HZ is associated with a transient increase in stroke and myocardial infarction risk, particularly after ophthalmic HZ. The strongest population-level cardiovascular evidence concerns ZVL, with a South Korean cohort showing reductions in major cardiovascular events, heart failure, and stroke sustained for up to 8 years; ZVL is now withdrawn in the United States and European Union. A natural-experiment study directly comparing the platforms found a further 9% reduction in cardiovascular burden with RZV versus ZVL over 7 years. Real-world cohorts in high-risk populations and a peer-reviewed meta-analysis also support cardiovascular benefit, although most pooled analyses combine RZV and ZVL, and no randomized trial has been designed specifically for cardiovascular outcomes.
Conclusion: Evidence increasingly supports a cardiovascular benefit of HZ vaccination, including with RZV currently in use, but remains predominantly observational or quasi-experimental. Dedicated randomized cardiovascular-outcome trials are needed.
期刊介绍：
Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.
Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.
Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
